Research Article
Serum Interleukin-23 in Polish Patients with Systemic Lupus Erythematosus: Association with Lupus Nephritis, Obesity, and Peripheral Vascular Disease
Table 1
Clinical characteristics of systemic lupus erythematosus patients and healthy controls.
| | Assessed parameters | Systemic lupus erythematosus patients
Mean ± SD
Median (Q1, Q3) | Healthy controls
Mean ± SD
Median (Q1, Q3) |
| | Age (years) | 44.5 ± 13.5 | 43.6 ± 13.1 | | Sex | F = 82; M = 12 | F = 21; M = 6 | | Disease duration (years) | 7.0 (4.0, 12.0) | — | | SLEDAI | | | | Low, n (%) | 52 (55.3%) | — | | Medium, n (%) | 33 (35.1%) | — | | High, n (%) | 9 (9.6%) | — | | APS, n (%) | 31 (33.3%) | — | | Lupus nephritis, n (%) | 24 (25.5%) | — | | Cerebrovascular manifestations | | | | TIA, n (%) | 2 (2.1%) | — | | Stroke, n (%) | 10 (10.6%) | — | | Cardiovascular manifestations | | | | CAD, n (%) | 11 (11.7%) | — | | MI, n (%) | 4 (4.3%) | — | | Raynaud’s phenomenon, n (%) | 25 (26.6%) | — | | Vasculitis, n (%) | 14 (14.9%) | — |
|
|
SLEDAI: systemic lupus erythematosus disease activity index; APS: antiphospholipid syndrome; TIA: transient ischemic attacks; CAD: coronary artery disease; MI: myocardial infarction.
|
